Table 3 Recommendations taking into account the balance of benefit (pain reduction and function improvement) and harm (adverse event)
From: Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system
Product | Grade of recommendation | Quality evidence | Balance benefit to harm |
|---|---|---|---|
Avocado/soybean unsaponifiables | Strong | Moderate | Avocado/soybean unsaponifiables advantageous |
Chondroitin sulfate | Strong | Moderate | Chondroitin sulfate advantageous |
Diacereine | Strong | Moderate | Diacereine advantageous |
Glucosamine sulfate | Strong | Moderate | Glucosamine sulfate advantageous |
Hyaluronic acid | Strong | Moderate | Hyaluronic acid advantageous |
Oral calcitonin | Weak | Low | Calcitonin not advantageous |
Risedronate | Strong | High | Risedronate not advantageous |
Strontium ranelate | Weak | Very low | Strontium ranelate advantageous |